

TERM	Province	DEFINITION
Disabling Attack	AB	- new/worsening symptoms lasting at least 48 hours in the absence of fever, preceded by stability for at least 1 month, not associated with steroid withdrawal - 1 or more gadolinium-enhancing T1 MRI lesions obtained at least 90 days after DMT initiation and at least 90 days before or after a relapse may substitute for 1 clinical relapse
	BC	- new/worsening symptoms lasting at least 24 hours in the absence of fever, preceded by stability for at least 1 month
	NB	- new/worsening symptoms lasting at least 24 hours in the absence of fever, preceded by stability for at least 1 month
	NL	- appearance of symptoms and signs compatible with MS, lasting greater than 24 hours and not due to a rise in temperature
	SK	- new/worsening symptoms lasting at least 24 hours in the absence of fever, preceded by stability for at least 1 month
	YK	- new/worsening symptoms lasting at least 24 hours in the absence of fever, preceded by stability for at least 1 month
Incapacitating Episode	QC	- episode during which a neurological examination confirms optical neuritis, posterior fossa syndrome (cerebral trunk and cerevet) or symptoms revealing that the spinal cord affected (myelitis)
Intolerant	AB	- serious adverse effects or contraindications to treatments as defined in the product monograph, or persisting adverse event unresponsive to recommended management techniques and which is incompatible with further use of that class of DMTs
Refractory	AB	- development of neutralizing antibodies to interferon beta - when interferon beta, glatiramer acetate, dimethyl fumarate, or teriflunomide are taken at the recommended doses for a full/adequate course within a consecutive 12 month period while the patient was on the MS DMT, the patient has been: 1) adherent to the MS DMT (>80% of approved doses administered) 2) experienced 2 or more relapses of MS confirmed by neurological deficits on exam a) 1st qualifying clinical relapse must have begun at least 1 month after treatment initiation b) both qualifying relapses must be classified with a relapse severity of moderate, severe, or very severe - with moderate relapses, modification or more time is required to carry out ADLs; with severe relapses, inability to carry out some ADLs; with very severe relapse, ADLs must be completed by others

Class	Product	Plan Type	BC	AB	SK	MB	ON	QC	NB	NS	PEI	NFLD	YK	Federal plans	
DMT	Avonex	Public	Special auth. (1st line)											Case-by-case approvals	
		Private	Coverage with criteria											N/A	
	Tecfidera	Public	Special auth. (1st line)											Case-by-case approvals	
		Private	Coverage with criteria											N/A	
	Tysabri	Public	Special auth. (3rd line)	Special auth. (2nd line)				Can be used 1st line for rapidly evolving disease	Special auth. (2nd line)	No coverage	Special auth. (3rd line)	Special auth. (2nd line)			Case-by-case approvals
		Private	Coverage with criteria											N/A	
	Plegridy	Public	No coverage	Special auth. (1st line)				No coverage	Special auth. (1st line)						Case-by-case approvals
		Private	Coverage with criteria											N/A	
Supportive Care	Fampyra	Public	No coverage				No public access but many approvals through compassionate use	No coverage						Case-by-case approvals	
Private		Coverage with criteria											N/A		